AVX-701 / Duke University Health System, AlphaVax - LARVOL DELTA

SAFYR: A Trial to Evaluate the Safety and Immunogenicity of an Investigational Vaccine for the Prevention of Yellow Fever, and of an Investigational Vaccine for the Prevention of Rabies, in Healthy Adults (clinicaltrials.gov) - P1 | N=144 | Recruiting | Sponsor: AstriVax Therapeutics

New P1 trial

Immunotherapy With CEA(6D) VRP Vaccine (AVX701) in Patients With Stage III Colorectal Cancer (clinicaltrials.gov) - P1; N=12; Recruiting; Sponsor: Duke University; Trial primary completion date: Jun 2016 ➔ Jun 2017

Trial primary completion date • Biosimilar • Colorectal Cancer • Gastrointestinal Cancer • Oncology

Immunotherapy With CEA(6D) VRP Vaccine (AVX701) in Patients With Stage III Colorectal Cancer (clinicaltrials.gov) - P1; N=12; Completed; Sponsor: Duke University; Active, not recruiting ➔ Completed

Clinical • Trial completion

Immunotherapy With CEA(6D) VRP Vaccine (AVX701) in Patients With Stage III Colorectal Cancer (clinicaltrials.gov) - P1; N=12; Active, not recruiting; Sponsor: Duke University; Trial completion date: Nov 2018 ➔ Jun 2019

Clinical • Trial completion date